France’s Nicox has announced that daily dosing of NCX 470 0.1%, a novel nitric oxide (NO)-donating bimatoprost eye drop, met ...

Exorphia announced that it has signed a business collaboration agreement with fellow Japanese company Rohto Pharmaceutical, following the capital alliance previously established between the two ...

UK and USA-listed PureTech Health has sought to show the strength of its position in idiopathic pulmonary fibrosis (IPF) at the 2025 IPF Summit this week in Boston, Massachusetts.

The UK’s NHS Business Services Authority's annual 'Prescribing for Diabetes - England 2015/16 to 2024/25' report reveals that diabetes treatments now account for 15% of all NHS prescription spending, ...

Danish allergy immunotherapy specialist ALK Abello today posted financial results which pleased investors, with its shares rising 6.2% to 199.50 kroner.

German gene therapies developer VeonGen Therapeutics today revealed that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to VG801, its ...

Celldex Therapeutics shares fell as much as 13% on Wednesday, after it posted mixed top-line results from its ongoing Phase II study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic ...

For what is reportedly the first time in decades, the American Academy of Pediatrics (AAP) has contradicted the US Centers for Disease Control and Prevention (CDC) over its recommended immunization ...

Japanese ophthalmology major Santen Pharmaceutical has licensed the Asia rights to Chinese biopharma RemeGen’s ...

Elix has announced that fellow Japanese firm Kyorin Pharmaceutical has adopted Elix Discovery, its proprietary AI-powered ...

Australia’s Neurizon Therapeutics, a biotech advancing innovative treatments for neurodegenerative diseases, has reported positive top-line results from the Open-Label Extension (OLE) study of its ...

Ireland-headquartered Jazz Pharmaceuticals and Denmark’s Saniona have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, ...